The manufacturer of Ozempic is “troubled” by the fact the drug, which was designed to help people with diabetes, is in short supply in the UAE because of the high number of consumers using it for its weight loss side-effects.
Danish pharmaceutical company Novo Nordisk introduced Wegovy, a drug meant to specifically tackle obesity, to the UAE market in November last year, in the hope of persuading non-diabetic users to stop buying Ozempic.
However, the sheer volume of diabetic and obese patients in the UAE, coupled with supply chain disruptions, continues to put a strain on the availability of Ozempic.
25 май 2024
